Profile data is unavailable for this security.
About the company
Natera, Inc. is a diagnostics company, which is focused on the development and commercialization of molecular testing services, applying its technology in the fields of women’s health, oncology and organ health. Its cell-free deoxyribonucleic acid (cfDNA) technology combines its molecular assays, which reliably measure many informative regions across the genome from samples as small as a single cell. The Company's product offerings include Panorama Non-Invasive Prenatal Test (NIPT), Vistara, Horizon Carrier Screening, Spectrum Preimplantation Genetics, Anora Miscarriage Test, Empower, and Prospera. The Company also offers Constellation, a cloud-based software platform that enables laboratory customers to gain access through the cloud to the Company’s algorithms and bioinformatics in order to validate and launch tests based on the Company’s technology. Its NIPT screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother.
- Revenue in USD (TTM)1.53bn
- Net income in USD-214.69m
- Incorporated2007
- Employees3.28k
- LocationNatera Inc13011 MCCALLEN PASSBUILDING A SUITE 100AUSTIN 78753United StatesUSA
- Phone+1 (650) 249-9090
- Fax+1 (302) 674-5266
- Websitehttps://www.natera.com/
Mergers & acquisitions
| Acquired company | NTRA:NSQ since announced | Transaction value |
|---|---|---|
| Invitae Corp-Reproductive Health Assets | 154.18% | 52.50m |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Universal Health Services, Inc. | 15.42bn | 1.03bn | 13.04bn | 73.35k | 13.14 | 1.97 | 8.01 | 0.8464 | 15.03 | 15.03 | 225.85 | 100.14 | 1.09 | -- | 6.93 | 210,194.40 | 7.41 | 6.44 | 8.68 | 7.63 | -- | -- | 6.78 | 6.55 | 1.28 | 7.70 | 0.4105 | 6.06 | 6.59 | 5.80 | 6.32 | -1.47 | 1.17 | 14.87 |
| Davita Inc | 12.67bn | 827.68m | 13.23bn | 70.00k | 17.69 | 35.07 | 7.17 | 1.06 | 9.28 | 9.28 | 141.50 | 4.68 | 0.7357 | 71.34 | 5.90 | 180,951.60 | 6.58 | 5.62 | 8.88 | 7.45 | 32.80 | 30.70 | 8.94 | 8.33 | 1.33 | 4.77 | 0.8115 | -- | 4.57 | 1.26 | 26.44 | 2.33 | -10.47 | -- |
| Tenet Healthcare Corp | 20.97bn | 3.13bn | 14.44bn | 78.14k | 4.73 | 3.67 | 2.94 | 0.6707 | 31.26 | 31.26 | 209.81 | 40.32 | 0.7364 | 9.49 | 7.15 | 268,376.30 | 13.86 | 3.61 | 20.23 | 5.09 | 82.61 | 82.97 | 18.83 | 4.95 | 1.52 | 5.37 | 0.6145 | 0.00 | 7.17 | 2.33 | 49.02 | 41.42 | 4.01 | -- |
| Molina Healthcare Inc | 39.20bn | 1.14bn | 16.85bn | 18.00k | 15.03 | 3.54 | 12.78 | 0.432 | 19.70 | 19.70 | 674.97 | 83.68 | 2.56 | -- | 13.71 | 2,177,722.00 | 7.47 | 7.62 | 16.58 | 16.80 | 16.12 | 15.99 | 2.92 | 3.04 | -- | 14.83 | 0.3465 | 0.00 | 6.56 | 12.52 | 37.75 | 9.06 | 22.87 | -- |
| Quest Diagnostics Inc | 9.54bn | 838.00m | 18.01bn | 40.00k | 22.00 | 2.70 | 13.70 | 1.92 | 7.45 | 7.45 | 84.79 | 60.79 | 0.645 | 34.77 | 7.18 | 238,475.00 | 5.87 | 9.28 | 6.77 | 10.81 | 32.94 | 36.64 | 9.10 | 12.97 | 1.17 | 8.87 | 0.4746 | 25.07 | -6.38 | 4.20 | -9.77 | 3.40 | 1.27 | 7.43 |
| Labcorp Holdings Inc | 12.71bn | 435.50m | 19.89bn | 67.00k | 46.54 | 2.46 | 19.02 | 1.58 | 5.16 | 5.16 | 150.40 | 97.61 | 0.7162 | 19.41 | 5.93 | 189,743.30 | 2.46 | 6.27 | 3.00 | 7.37 | 27.92 | 32.33 | 3.44 | 9.51 | 1.30 | 5.59 | 0.455 | -- | 2.51 | 1.42 | -62.16 | -16.40 | 3.62 | -- |
| Natera Inc | 1.53bn | -214.69m | 20.76bn | 3.28k | -- | 23.93 | -- | 13.67 | -1.77 | -1.77 | 12.59 | 7.08 | 1.01 | 14.29 | 5.45 | 466,774.80 | -14.14 | -36.17 | -17.55 | -46.60 | 57.66 | 45.88 | -14.01 | -56.15 | 4.23 | -- | 0.2947 | -- | 31.99 | 33.26 | 20.63 | -- | 58.81 | -- |
| Centene Corp | 161.73bn | 3.07bn | 29.84bn | 67.70k | 10.47 | 1.13 | 7.09 | 0.1884 | 5.77 | 5.77 | 303.72 | 53.53 | 1.94 | -- | 9.57 | 2,388,863.00 | 3.66 | 2.58 | 6.39 | 3.99 | 10.37 | 11.59 | 1.89 | 1.37 | -- | 4.06 | 0.3911 | 0.00 | 6.54 | 20.70 | 124.79 | 24.59 | 3.43 | -- |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 30 Sep 2024 | 11.25m | 9.09% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 6.18m | 5.00% |
| Farallon Capital Management LLCas of 30 Sep 2024 | 4.56m | 3.69% |
| JPMorgan Investment Management, Inc.as of 30 Sep 2024 | 4.08m | 3.30% |
| Duquesne Family Office LLCas of 30 Sep 2024 | 3.57m | 2.88% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 3.49m | 2.83% |
| Fred Alger Management LLCas of 30 Sep 2024 | 3.12m | 2.53% |
| T. Rowe Price Associates, Inc. (IM)as of 30 Sep 2024 | 2.77m | 2.24% |
| Wellington Management Co. LLPas of 30 Sep 2024 | 2.65m | 2.14% |
| RTW Investments LPas of 30 Sep 2024 | 2.59m | 2.10% |
